Aspirin curcumin ester loaded biomimetic nanodrug improves cognitive deficits in a mouse model of Alzheimer's disease by regulating M1/M2 microglial polarization
Source abstract
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder, tightly related with microglia phenotypic polarization, which finally results in the stimulation of β-amyloid peptides (Aβ) and promotion of phagocytosis of neuronal synaptic structures. Thus, constructing drug system to reverse microglia phenotypic polarization is highly desired for AD therapy. In this study, we developed a nano delivery system (denoted as M@CA@GP NPs) by loading aspirin curcumin ester (CA) on the graphene oxide quantum dots (GOQDs) for AD therapy. With the modification of hybrid cell membrane, this nanoconjugate can efficiently deliver drugs to the brain and regulate the inflammatory microenvironment to improve learning and memory. Moreover, this targeting strategy exhibits the ability of regulating the microglial cell phenotype, promoting Aβ phagocytosis, and maintaining synaptic plasticity with prolonged circulation time and high biocompatibility. Taken together, our results demonstrate that the M@CA@GP NPs can alleviate glial cell activation, decrease Aβ burden, and eventually enhance cognitive functions in APPswe/PSEN1dE9 model mice. These results indicate that M@CA@GP NPs can be a promising therapeutic agent for the treatment of AD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Advanced Nanomaterials in Catalysis · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Microglia-mediated neuroinflammation in neurodegenerative diseases10.1016/j.semcdb.2019.05.004 ↗
2. Microglia in neurodegeneration10.1038/s41593-018-0242-x ↗
3. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes10.1186/s40035-020-00221-2 ↗
4. Curcumin in health and diseases: Alzheimer's disease and curcumin analogues, derivatives, and hybrids10.3390/ijms21061975 ↗
5. The mechanisms of action of curcumin in Alzheimer's disease10.3233/JAD-170188 ↗
6. Aspirin binds to PPARalpha to stimulate hippocampal plasticity and protect memory10.1073/pnas.1802021115 ↗
7. PPARα serves as a new receptor of aspirin for neuroprotection10.1002/jnr.24561 ↗
8. Aspirin-Mediated acetylation protects against multiple neurodegenerative pathologies by impeding protein aggregation10.1089/ars.2016.6978 ↗
9. Curcumin and heme oxygenase: neuroprotection and beyond10.3390/ijms20102419 ↗
10. Curcumin in clinical practice: myth or reality?10.1016/j.tips.2009.04.004 ↗
11. Curcumin acetylsalicylate extends the lifespan of10.3390/molecules26216609 ↗
12. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies10.1016/j.biomaterials.2019.119491 ↗
13. Systematic assessment of the toxicity and potential mechanism of graphene derivatives in vitro and in vivo10.1093/toxsci/kfy235 ↗
14. Graphene-based nanomaterials for drug delivery and tissue engineering10.1016/j.jconrel.2013.10.017 ↗
15. Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors10.1016/j.nano.2013.12.006 ↗
16. Graphene oxide quantum dots reduce oxidative stress and inhibit neurotoxicity in vitro and in vivo through catalase-like activity and metabolic regulation10.1002/advs.201700595 ↗
17. Fluorogenic resveratrol-confined graphene oxide for economic and rapid detection of Alzheimer's disease10.1021/am5010909 ↗
18. Graphene quantum dots for the inhibition of beta amyloid aggregation10.1039/C5NR06282A ↗
19. Molecular dynamics simulations reveal the mechanism of graphene oxide nanosheet inhibition of Abeta1-42 peptide aggregation10.1039/C9CP01803D ↗
20. Reduced graphene oxide induces transient blood-brain barrier opening: an in vivo study10.1186/s12951-015-0143-z ↗
21. Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson's disease10.1039/D0BM01765E ↗
22. Cell membrane coating nanotechnology10.1002/adma.201706759 ↗
23. Cytomembrane-Mediated transport of metal ions with biological specificity10.1002/advs.201900835 ↗
24. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors10.1002/adma.201602173 ↗
25. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis10.1038/s41467-020-18626-y ↗
26. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application10.1016/j.apsb.2019.01.011 ↗
27. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma10.1021/acsnano.7b08355 ↗
28. RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer10.1016/j.biomaterials.2019.119301 ↗
29. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition10.1016/j.actbio.2020.06.025 ↗
30. A smart drug-delivery nanosystem based on carboxylated graphene quantum dots for tumor-targeted chemotherapy10.2217/nnm-2018-0378 ↗
31. Neuronal protein farnesylation regulates hippocampal synaptic plasticity and cognitive function10.1007/s12035-020-02169-w ↗
32. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth10.1523/JNEUROSCI.4872-08.2009 ↗
33. Key for crossing the BBB with nanoparticles: the rational design10.3762/bjnano.11.72 ↗
34. Self-distinguishing and stimulus-responsive carrier-free theranostic nanoagents for imaging-guided chemo-photothermal therapy in small-cell lung cancer10.1021/acsami.0c18273 ↗
35. Nano carriers for drug transport across the blood-brain barrier10.1080/1061186X.2016.1184272 ↗
36. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine10.1039/D0CS01127D ↗
37. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes10.1016/j.ymthe.2005.03.038 ↗
38. Biocompatibility and nanostructured materials: applications in nanomedicine10.1080/21691401.2016.1178134 ↗
39. Biomimetic nanoparticles loading with gamabutolin-indomethacin for chemo/photothermal therapy of cervical cancer and anti-inflammation10.1016/j.jconrel.2021.09.034 ↗
40. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy10.1021/acsnano.6b04695 ↗
41. Artemisinin and Procyanidins loaded multifunctional nanocomplexes alleviate atherosclerosis via simultaneously modulating lipid influx and cholesterol efflux10.1016/j.jconrel.2021.12.021 ↗
42. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes10.1021/acs.nanolett.6b02786 ↗
43. Biocompatibility in regenerative nanomedicine10.2217/nnm-2019-0140 ↗
44. Effects of core size and PEG coating layer of iron oxide nanoparticles on the distribution and metabolism in mice10.2147/IJN.S165451 ↗
45. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy10.1016/j.addr.2009.03.009 ↗
46. Andrographolide ameliorates neuroinflammation in APP/PS1 transgenic mice10.1016/j.intimp.2021.107808 ↗
47. Microglia function in the central nervous system during health and neurodegeneration10.1146/annurev-immunol-051116-052358 ↗
48. On the integration of space, time, and memory10.1016/j.neuron.2017.06.036 ↗
49. Adult hippocampal neurogenesis and its role in Alzheimer's disease10.1186/1750-1326-6-85 ↗
50. Microglia-Mediated synapse loss in Alzheimer's disease10.1523/JNEUROSCI.1136-17.2017 ↗